|Tested species reactivity||Human, Mouse|
|Published species reactivity||Human|
|Host / Isotype||Mouse / IgG1|
|Immunogen||Recombinant Abl protein|
|Storage buffer||PBS, pH 7.4, with 0.2% BSA|
|Contains||0.09% sodium azide|
|Storage Conditions||4° C|
|Tested Applications||Dilution *|
|Immunohistochemistry (Paraffin) (IHC (P))||12-24 µg/ml|
|Immunoprecipitation (IP)||2 µg/mg lysate|
|Western Blot (WB)||1 µg/mL|
* Suggested working dilutions are given as a guide only. It is recommended that the user titrate the product for use in their own experiment using appropriate negative and positive controls.
|Immunohistochemistry (IHC)||See 4 publications below|
MA5-14395 targets c-Abl in IF, IHC (P), IP, and WB applications and shows reactivity with Human and mouse samples.
The c-Abl proto-oncogene encodes a protein tyrosine kinase that is located in the cytoplasm and nucleus. In chronic myelogenous leukemia and in a subset of acute lymphoblastic leukemias, the c-Abl proto-oncogene undergoes a (9;22) chromosomal translocation producing a novel rearranged chromosome (the Philadelphia chromosome) As the result of the fusion of c-Abl sequences from chromosome 9 to the Bcr gene on chromosome 22. The molecular consequence of this translocation is the generation of a chimeric Bcr/Abl mRNA encoding activated Abl protein tyrosine kinase.
For Research Use Only. Not for use in diagnostic procedures. Not for resale without express authorization.
Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant low-grade serous carcinoma of the ovary, peritoneum, or fallopian tube.
MA5-14395 was used in immunohistochemistry to perform a phase II clinical trial of imatinib mesylate in patients with recurrent low-grade serous carcinoma of the ovary, peritoneum or fallopian tube
|Noguera IR,Sun CC,Broaddus RR,Branham D,Levenback CF,Ramirez PT,Sood AK,Coleman RL,Gershenson DM||Gynecologic oncology (125:640)||2012|
Phase II trial of imatinib mesylate in patients with recurrent platinum- and taxane-resistant epithelial ovarian and primary peritoneal cancers.
MA5-14395 was used in immunohistochemistry to study the therapeutic efficacy of imatinib mesylate in patients with recurrent ovarian and primary peritoneal cancer
|Coleman RL,Broaddus RR,Bodurka DC,Wolf JK,Burke TW,Kavanagh JJ,Levenback CF,Gershenson DM||Gynecologic oncology (101:126)||2006|
Expression of imatinib mesylate-targeted kinases in endometrial carcinoma.
MA5-14395 was used in immunohistochemistry to study the expression of imatinib mesylate-targeted kinases in endometrial carcinoma
|Slomovitz BM,Broaddus RR,Schmandt R,Wu W,Oh JC,Ramondetta LM,Burke TW,Gershenson DM,Lu KH||Gynecologic oncology (95:32)||2004|
Expression of c-ABL, c-KIT, and platelet-derived growth factor receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium.
MA5-14395 was used in immunohistochemistry to study expression of c-ABL, c-KIT, and PDGF receptor-beta in ovarian serous carcinoma and normal ovarian surface epithelium
|Schmandt RE,Broaddus R,Lu KH,Shvartsman H,Thornton A,Malpica A,Sun C,Bodurka DC,Gershenson DM||Cancer (98:758)||2003|